-transparent.png){kind=logo}
BACKGROUND Once-daily dosing with an effective inhaled corticosteroid (ICS) would likely enhance compliance and, therefore, aid in the management of asthma. OBJECTIVE Several once-daily dosing regimens of mometasone furoate (MF) administered by dry powder inhaler (DPI) were compared with a twice-daily dosing regimen in 286 patients with mild to moderate persistent asthma who were previously being treated with ICS. METHODS During a 2-week open-label phase, patients received MF-DPI, 200 microg twice daily. They were then randomized to continue MF-DPI, 200 microg twice-daily treatment or to receive MF-DPI, 200 microg once daily in the morning (AM), 200 microg once daily in the evening (PM), 400 microg once daily AM, or placebo as part of the 12-week, double-blind phase. The primary efficacy variable was the mean change from the baseline to endpoint (last evaluable observation) for FEV1. RESULTS Once-daily MF-DPI, 400 microg, AM maintained FEV1, and morning peak expiratory flow rate, FVC, FEF25%-75%, and asthma symptom scores, at levels similar to those for MF-DPI, 200 microg twice daily and significantly better than placebo. Once-daily MF-DPI, 200 microg, PM was effective in maintaining pulmonary function, but was less effective on other efficacy measures. In comparison to the other MF-DPI groups, once-daily MF-DPI, 200 microg, AM was not as effective overall. The incidence of local adverse events, including oral candidiasis, was low with all dosages. CONCLUSIONS Once-daily MF-DPI, 400 microg, AM was as effective as MF-DPI, 200 microg twice daily, whereas once-daily MF-DPI, 200 microg, was more effective when administered in the evening compared with morning, for patients receiving ICS therapy. Once-daily dosing offers an effective and convenient treatment that could aid compliance in the treatment of asthma.
M Noonan, and
J P Karpel, and
G W Bensch, and
J W Ramsdell, and
D R Webb, and
K B Nolop, and
B N Lutsky
April 2000,
Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology,
M Noonan, and
J P Karpel, and
G W Bensch, and
J W Ramsdell, and
D R Webb, and
K B Nolop, and
B N Lutsky
October 2008,
Respiratory medicine,
M Noonan, and
J P Karpel, and
G W Bensch, and
J W Ramsdell, and
D R Webb, and
K B Nolop, and
B N Lutsky
November 2007,
Current medical research and opinion,
M Noonan, and
J P Karpel, and
G W Bensch, and
J W Ramsdell, and
D R Webb, and
K B Nolop, and
B N Lutsky
January 2010,
BMC pulmonary medicine,
M Noonan, and
J P Karpel, and
G W Bensch, and
J W Ramsdell, and
D R Webb, and
K B Nolop, and
B N Lutsky
December 2011,
Expert opinion on pharmacotherapy,
M Noonan, and
J P Karpel, and
G W Bensch, and
J W Ramsdell, and
D R Webb, and
K B Nolop, and
B N Lutsky
January 2001,
Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine,
M Noonan, and
J P Karpel, and
G W Bensch, and
J W Ramsdell, and
D R Webb, and
K B Nolop, and
B N Lutsky
November 2006,
Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology,
M Noonan, and
J P Karpel, and
G W Bensch, and
J W Ramsdell, and
D R Webb, and
K B Nolop, and
B N Lutsky
November 2000,
The European respiratory journal,
M Noonan, and
J P Karpel, and
G W Bensch, and
J W Ramsdell, and
D R Webb, and
K B Nolop, and
B N Lutsky
January 2016,
Biological & pharmaceutical bulletin,
M Noonan, and
J P Karpel, and
G W Bensch, and
J W Ramsdell, and
D R Webb, and
K B Nolop, and
B N Lutsky
November 2007,
Expert opinion on pharmacotherapy,
